The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Lipid Nanoparticles for Drug Delivery
Open accessAbstract
Lipid nanoparticles have attracted significant interests in the last two decades, and have achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the same time, lipid nanoparticles have also demonstrated enormous potential in delivering nucleic acid drugs as evidenced by the approval of two RNA therapies and mRNA COVID‐19 vaccines. In this review, an overview on different classes of lipid nanoparticles, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, is first provided, followed by the introduction of their preparation methods. Then the characterizations of lipid nanoparticles are briefly reviewed and their applications in encapsulating and delivering hydrophobic drugs, hydrophilic drugs, and RNAs are highlighted. Finally, various applications of lipid nanoparticles for overcoming different delivery challenges, including crossing the blood–brain barrier, targeted delivery, and various routes of administration, are summarized. Lipid nanoparticles as drug delivery systems offer many attractive benefits such as great biocompatibility, ease of preparation, feasibility of scale‐up, nontoxicity, and targeted delivery, while current challenges in drug delivery warrant future studies about structure–function correlations, large‐scale production, and targeted delivery to realize the full potential of lipid nanoparticles for wider clinical and pharmaceutical applications in future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, P. C., Zhang, L., Wang, T., Liu, Q., Wang, J., Wang, Y., Tu, Z., & Lin, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259428 · Cited by 39
RetractedEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
U1 snRNP regulates cancer cell migration and invasion in vitro
Oh, J.-M., Venters, C. C., Di, C., Pinto, A. M., Wan, L., Younis, I., Cai, Z., Arai, C., So, B. R., Duan, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13993-7 · Cited by 7,157
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Nanocapsule formation by interfacial polymer deposition following solvent displacement
Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90281-0 · Cited by 2,288
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Cited by
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 688
Protein Corona Formation on Lipid Nanoparticles Negatively Affects the NLRP3 Inflammasome Activation
Debnath, M., Forster, J., Ramesh, A., & Kulkarni, A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00329 · Cited by 60
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X.
- Venue
- Advanced NanoBiomed Research
- Publisher
- Wiley
- Published
- 2021-11-25
- Volume
- 2
- Issue
- 2
- ISSN
- 2699-9307 (ISSN-L)
- OpenAlex
- W3216282807
- Cited by
- 545
- References
- 159
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Nanoparticles for Drug Delivery. https://app.cochat.ai/papers/10.1002/anbr.202100109
- The paper
- Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022). Lipid Nanoparticles for Drug Delivery. Advanced NanoBiomed Research. https://doi.org/10.1002/anbr.202100109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.